RESUMO
Insulin-dependent diabetes mellitus (IDDM) induces plasma amino acid (AA) abnormalities, including low alanine and high branched-chain (BCAA). While insulin treatment restores plasma AA pattern, proline, methionine, valine, isoleucine, and total BCAA remain elevated in skeletal muscle intracellular water. This suggests that the restoration of plasma AA concentrations is not a satisfactory index of recovered AA metabolism in IDDM.
Assuntos
Aminoácidos/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Insulina/uso terapêutico , Músculos/metabolismo , Adulto , Aminoácidos/sangue , Aminoácidos de Cadeia Ramificada/metabolismo , Água Corporal/metabolismo , Cloretos/metabolismo , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Espaço Extracelular/metabolismo , Feminino , Humanos , Líquido Intracelular/metabolismo , Masculino , Pessoa de Meia-IdadeAssuntos
Prolactina/metabolismo , Somatostatina/farmacologia , Adulto , Feminino , Humanos , Masculino , Prolactina/sangueRESUMO
Human pancreatic polypeptide is the only hormone so far reported which clearly suppresses somatostatin release, suggesting that this peptide may have a role in controlling somatostatin secretion from the gut and pancreas. In this study endogenous high circulating human pancreatic polypeptide concentrations in patients with chronic renal failure do not decrease somatostatin circulating levels. The reduced clearance rate of somatostatin in chronic renal failure may partially account for the normal circulating levels of somatostatin observed in our patients with respect to controls. Renal insufficiency may, itself, induce an increase in some gastrointestinal peptides capable of stimulating somatostatin secretion.